LONG BEACH, Calif. — EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet age-related macular degeneration, according to a press release.
More than 400 patients have been enrolled in the trial and undergone randomization over the past 7 months. EyePoint’s first phase 3 trial of Duravyu, LUGANO, completed enrollment in May.
{{VIDEO}}
Both trials will assess the efficacy and safety of sustained-release Duravyu (vorolanib intravitreal insert) in patients with wet AMD who have been randomly assigned to receive either